Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lipoprotein apheresis in the era of new lipid-lowering therapies.

European heart journal·2026
Same author

Treatment of Clinically Diagnosed Alzheimer's Disease by External Counterpulsation A Randomized Clinical Trial.

American journal of Alzheimer's disease and other dementias·2026
Same author

Evinacumab with or without lipoprotein apheresis in homozygous familial hypercholesterolaemia.

European journal of preventive cardiology·2026
Same author

Evinacumab in patients aged 5-17 years with homozygous familial hypercholesterolemia.

Atherosclerosis·2026
Same author

A Personalized Medicine Approach is Best for Patients with Homozygous Familial Hypercholesterolemia.

Medical research archives·2025
Same author

Pelacarsen: Mechanism of action and Lp(a)-lowering effect.

Journal of clinical lipidology·2025
Same journal

Navigating Adrenal Disease: A Comprehensive, Practical Guide for the Clinician.

Endocrinology and metabolism clinics of North America·2026
Same journal

Adrenal Disorders in Pregnancy.

Endocrinology and metabolism clinics of North America·2026
Same journal

Diagnosis and Management of Adrenocortical Carcinoma.

Endocrinology and metabolism clinics of North America·2026
Same journal

Pheochromocytomas and Paragangliomas.

Endocrinology and metabolism clinics of North America·2026
Same journal

Hereditary Conditions Associated with Adrenocortical Carcinoma, Pheochromocytoma, and Other Adrenal Tumors: Genetic Testing and Management Recommendations.

Endocrinology and metabolism clinics of North America·2026
Same journal

Primary Bilateral Macronodular Adrenal Hyperplasia.

Endocrinology and metabolism clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Mar 25, 2026

Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate
11:13

Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate

Published on: May 9, 2019

9.4K

Lipoprotein Apheresis.

Patrick M Moriarty1, Linda Hemphill2

  • 1Division of Clinical Pharmacology and Atherosclerosis/Lipoprotein-Apheresis Center, University of Kansas Medical Center, 3901 Rainbow Boulevard, Mail Stop 3008, Kansas City, KS 66160, USA.

Endocrinology and Metabolism Clinics of North America
|February 20, 2016
PubMed
Summary
This summary is machine-generated.

Lipoprotein apheresis (LA) therapy effectively lowers low-density lipoprotein cholesterol (LDL-C) and reduces cardiovascular events in familial hypercholesterolemia (FH) patients. This treatment also decreases Lp(a) levels, inflammatory markers, and blood viscosity.

Keywords:
AtherosclerosisCVDFamilial hypercholesterolemiaLDL-CLipoprotein apheresisLp(a)

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.7K
Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification
10:39

Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification

Published on: November 28, 2016

11.9K

Related Experiment Videos

Last Updated: Mar 25, 2026

Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate
11:13

Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate

Published on: May 9, 2019

9.4K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.7K
Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification
10:39

Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification

Published on: November 28, 2016

11.9K

Area of Science:

  • Cardiology
  • Metabolic Disorders
  • Vascular Medicine

Background:

  • Familial hypercholesterolemia (FH) patients experience premature atherosclerosis and cardiovascular disease (CVD).
  • Standard lipid-lowering medications may not sufficiently reduce elevated low-density lipoprotein cholesterol (LDL-C) in FH patients.
  • Lipoprotein apheresis (LA) is an established therapy for managing severe hypercholesterolemia.

Purpose of the Study:

  • To evaluate the clinical benefits of Lipoprotein apheresis (LA) in patients with familial hypercholesterolemia (FH).
  • To assess the efficacy of LA in reducing cardiovascular disease (CVD) events and specific lipid markers.

Main Methods:

  • Lipoprotein apheresis (LA) therapy administered to patients with familial hypercholesterolemia (FH).
  • Monitoring of low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) [Lp(a)] levels before and after treatment.
  • Assessment of cardiovascular disease (CVD) event rates and other biomarkers like inflammatory markers and blood viscosity.

Main Results:

  • Lipoprotein apheresis (LA) achieved over 60% reduction in LDL-C levels in FH patients.
  • LA therapy demonstrated a significant reduction in cardiovascular disease (CVD) events.
  • LA treatment also led to decreased levels of Lp(a), inflammatory markers, and improved blood viscosity.

Conclusions:

  • Lipoprotein apheresis (LA) is a clinically beneficial therapy for reducing cardiovascular events in familial hypercholesterolemia (FH) patients.
  • LA effectively lowers both LDL-C and Lp(a) levels, contributing to reduced CVD risk.
  • The therapy offers additional benefits by reducing inflammatory markers and blood viscosity in FH patients.